Optimer Company Description
Optimer Pharmaceuticals has something for those "oh no, gotta go" moments. The company develops drug candidates for treating a variety of gastrointestinal infections. Its lead candidate, OPT-80, is in later-stage clinical trials for Clostridium difficile-associated diarrhea, commonly acquired in hospitals. It is also being tested for its ability to inhibit the growth of staph bacteria. Its Prulifloxacin antibiotic is also in later trials for the treatment of infectious traveler's diarrhea. Through the manipulation of carbohydrates, the company is using its OPopS technology to identify other potential drug candidates for diseases such as breast cancer, osteoarthritis, and respiratory tract infections.
View the Comprehensive Company Description for Optimer
The Company Description provides a historical perspective of Optimer's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of Optimer's evolution in the marketplace.
